Skip to main content
SpringerLink
Log in

Novel Targets in Systemic Lupus Erythematosus

  • Reference work entry
  • First Online:
Encyclopedia of Medical Immunology

  • 491 Accesses

Synonyms

Biologics; Small molecule inhibitors

Definition

Treatment of autoimmune diseases such as systemic lupus erythematosus invariably requires the use of immunosuppressive medications. Better understanding of the pathophysiology of these diseases has allowed the identification of new selective targets for therapeutic intervention.

Historical Background

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease associated with significant morbidity and mortality. The pathogenesis of SLE involves multiple levels of immune dysfunction, as well as multiple organ systems, and therefore, therapy has traditionally required broad-based immunosuppression. Corticosteroids in particular are the mainstay of SLE treatment. Though effective, use of steroids is limited by their long-term toxicities. Other therapies such as cyclophosphamide, mycophenolate mofetil, and azathioprine have markedly improved patient outcomes over the past 20 years. However, these agents still carry risks of...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 799.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 949.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abbas AK, Lichtman AH, et al. Cellular and molecular immunology. Philadelphia: Saunders/Elsevier; 2010.

    Google Scholar 

  • Alaaeddine N, Hassan GS, et al. CD154: an immunoinflammatory mediator in systemic lupus erythematosus and rheumatoid arthritis. Clin Dev Immunol. 2012;2012:490148.

    PubMed  PubMed Central  Google Scholar 

  • Bao L, Quigg RJ. Complement in lupus nephritis: the good, the bad, and the unknown. Semin Nephrol. 2007;27(1):69–80.

    PubMed  CAS  Google Scholar 

  • Colonna L, Catalano G, et al. Therapeutic targeting of Syk in autoimmune diabetes. J Immunol. 2010;185(3):1532–43.

    PubMed  CAS  PubMed Central  Google Scholar 

  • Davidson A. Targeting BAFF in autoimmunity. Curr Opin Immunol. 2010;22(6):732–9.

    PubMed  CAS  PubMed Central  Google Scholar 

  • Deshmukh US, Bagavant H, et al. Role of anti-DNA antibodies in the pathogenesis of lupus nephritis. Autoimmun Rev. 2006;5(6):414–8.

    PubMed  CAS  Google Scholar 

  • Ginzler EM, Wax S, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14(1):R33.

    PubMed  CAS  PubMed Central  Google Scholar 

  • Hazeldine J, Arlt W, et al. Dehydroepiandrosterone as a regulator of immune cell function. J Steroid Biochem Mol Biol. 2010;120(2–3):127–36.

    PubMed  CAS  Google Scholar 

  • Hedrich CM, Tsokos GC. Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends Mol Med. 2011;17(12):714–24.

    PubMed  CAS  PubMed Central  Google Scholar 

  • Kyttaris VC, Tsokos GC. Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus. Curr Opin Rheumatol. 2011;23(5):449–53.

    PubMed  CAS  PubMed Central  Google Scholar 

  • Lafyatis R, York M, et al. Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum. 2006;54(10):3068–70.

    PubMed  CAS  Google Scholar 

  • Lateef A, Petri M. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2010;22(5):504–9.

    PubMed  Google Scholar 

  • Lichtman EI, Helfgott SM, et al. Emerging therapies for systemic lupus erythematosus – focus on targeting interferon-alpha. Clin Immunol. 2012;143(3):210–21.

    PubMed  CAS  PubMed Central  Google Scholar 

  • Lo MS, Tsokos GC. Treatment of systemic lupus erythematosus: new advances in targeted therapy. Ann N Y Acad Sci. 2012;1247:138–52.

    PubMed  CAS  Google Scholar 

  • Lu LD, Stump KL, et al. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2. J Immunol. 2011;187(7):3840–53.

    PubMed  CAS  Google Scholar 

  • Perl A. Systems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment. Autoimmunity. 2010;43(1):32–47.

    PubMed  CAS  PubMed Central  Google Scholar 

  • Rickert RC, Jellusova J, et al. Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev. 2011;244(1):115–33.

    PubMed  CAS  PubMed Central  Google Scholar 

  • Stirzaker RA, Biswas PS, et al. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/WF1 female mice. Lupus. 2012;21(6):656–61.

    PubMed  CAS  Google Scholar 

  • Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365(22):2110–21.

    PubMed  CAS  Google Scholar 

  • Weinblatt ME, Kavanaugh A, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363(14):1303–12.

    PubMed  CAS  Google Scholar 

  • Zerbini CA, Lomonte AB. Tofacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2012;8(4):319–31.

    PubMed  CAS  Google Scholar 

  • Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond). 2012;122(11):487–511.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Immunology, Department of Medicine, Boston Children’s Hospital, 300 Longwood Ave, Boston, MA, 02115, USA

    Mindy S. Lo

Authors
  1. Mindy S. Lo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mindy S. Lo .

Editor information

Editors and Affiliations

  1. Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia

    Ian R. Mackay

  2. Center for Autoimmune Disease Research, Department of Molecular Microbiology and Immunology, Department of Pathology, Johns Hopkins University, Baltimore, MD, USA

    Noel R. Rose

  3. The Feinstein Institute for Medical Research, Manhasset, NY, USA

    Betty Diamond

  4. The Feinstein Institute for Medical Research, Manhasset, NY, USA

    Anne Davidson

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this entry

Cite this entry

Lo, M.S. (2014). Novel Targets in Systemic Lupus Erythematosus. In: Mackay, I.R., Rose, N.R., Diamond, B., Davidson, A. (eds) Encyclopedia of Medical Immunology. Springer, New York, NY. https://doi.org/10.1007/978-0-387-84828-0_374

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-84828-0_374

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-84827-3

  • Online ISBN: 978-0-387-84828-0

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation